Because NF-κB has been shown to mediate cellular growth and survival in MCL [25], we evaluated whether cells possessing bortezomib-resistant constitutive NF-κB activity would in fact demonstrate a survival advantage in the face of bortezomib treatment. This evidence concerns the gene NFKB1 and mantle cell lymphoma.